Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

2.32USD
19 Oct 2018
Change (% chg)

-- (--)
Prev Close
$2.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
192,860
52-wk High
$6.97
52-wk Low
$2.06

Latest Key Developments (Source: Significant Developments)

Tetraphase Announces Adoption Of Commission Decision Granting Marketing Authorisation Approval In EU For Xerava
Thursday, 20 Sep 2018 01:08pm EDT 

Sept 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES ADOPTION OF COMMISSION DECISION GRANTING MARKETING AUTHORISATION APPROVAL IN THE EUROPEAN UNION FOR XERAVA (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.SAYS PHASED COMMERCIAL LAUNCH EXPECTED IN FIRST HALF OF 2019.SAYS ON TRACK TO LAUNCH XERAVA IN EUROPE VIA PHASED INTRODUCTION, BEGINNING WITH GERMANY AND UK, IN EARLY 2019.  Full Article

Tetraphase Pharmaceuticals Elects Christopher Watt As Principal Financial Officer
Monday, 19 Mar 2018 04:33pm EDT 

March 19 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS - BOARD ELECTED CHRISTOPHER WATT AS PRINCIPAL FINANCIAL OFFICER & PRINCIPAL ACCOUNTING OFFICER UNTIL CFO IS NAMED.TETRAPHASE SAYS WATT HAS SERVED AS SVP, FINANCE SINCE JAN. 2017 - SEC FILING.  Full Article

Tetraphase Pharma Q4 Loss Per Share $0.46
Tuesday, 6 Mar 2018 04:40pm EST 

March 6 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, HIGHLIGHTS ACHIEVEMENTS AND KEY 2018 MILESTONES.Q4 LOSS PER SHARE $0.46.Q4 REVENUE $2.5 MILLION VERSUS $1.1 MILLION.Q4 REVENUE VIEW $2.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline
Tuesday, 27 Feb 2018 08:00am EST 

Feb 27 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI).TETRAPHASE PHARMACEUTICALS INC - PDUFA GOAL DATE FOR COMPLETION OF FDA'S REVIEW OF ERAVACYCLINE NDA IS SET FOR AUGUST 28, 2018.  Full Article

Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines
Tuesday, 20 Feb 2018 04:01pm EST 

Feb 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA.TETRAPHASE PHARMACEUTICALS - WILL RECEIVE INITIAL UPFRONT PAYMENT OF $7.0 MILLION, MAY RECEIVE CLINICAL AND REGULATORY MILESTONES OF UP TO $16.5 MILLION.TETRAPHASE PHARMA-CO ‍MAY RECEIVE CLINICAL, REGULATORY MILESTONES OF UP TO $16.5 MILLION AS WELL AS ANNUAL SALES MILESTONES OF UP TO $20.0 MILLION​.TETRAPHASE PHARMACEUTICALS - ‍EVEREST WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT & COMMERCIALIZATION OF ERAVACYCLINE IN TERRITORIES​.TETRAPHASE PHARMACEUTICALS-CO, EVEREST TO ESTABLISH JOINT STEERING COMMITTEE TO REVIEW, OVERSEE ALL OF EVEREST'S DEVELOPMENT, COMMERCIALIZATION PLANS.TETRAPHASE PHARMACEUTICALS - TO BE ELIGIBLE TO RECEIVE DOUBLE DIGIT TIERED ROYALTIES ON NET SALES OF ERAVACYCLINE IN AREAS UNDER AGREEMENT.TETRAPHASE PHARMA - ENTERED AGREEMENT WITH EVEREST MEDICINES TO DEVELOP, COMMERCIALIZE ERAVACYCLINE IN HONG KONG, SOUTH KOREA, SINGAPORE, AMONG OTHERS.  Full Article

Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI
Tuesday, 13 Feb 2018 04:01pm EST 

Feb 13 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI).TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE DID NOT ACHIEVE CO-PRIMARY ENDPOINTS IN CUTI TRIAL​.TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE WAS WELL TOLERATED IN IGNITE3​.TETRAPHASE - ‍CONTINUES TO PREPARE FOR COMMERCIALIZATION OF ERAVACYCLINE AS A TREATMENT FOR CIAI IN U.S. AND EUROPE, ASSUMING REGULATORY APPROVAL​.TETRAPHASE PHARMACEUTICALS INC - ‍CONTINUE TO MOVE FORWARD WITH OUR REGISTRATION STRATEGY FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTIONS​.TETRAPHASE PHARMACEUTICALS- STUDY FAILED TO MEET CO-PRIMARY EFFICACY ENDPOINTS OF RESPONDER RATE IN MICRO-ITT POPULATION AT EOI TREATMENT VISIT, TOC VISIT.  Full Article

Tetraphase Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln
Thursday, 25 Jan 2018 05:32pm EST 

Jan 25 (Reuters) - Tetraphase Pharmaceuticals Inc ::FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections
Tuesday, 2 Jan 2018 04:30pm EST 

Jan 2 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI).TETRAPHASE PHARMACEUTICALS INC - NDA SUBMISSION INCLUDES DATA FROM IGNITE1 AND IGNITE 4 PHASE 3 CLINICAL TRIALS.  Full Article

Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14
Wednesday, 20 Dec 2017 05:14pm EST 

Dec 20 (Reuters) - Millennium Management Llc::MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING.  Full Article

Tetraphase Pharmaceuticals Q3 loss per share $0.63
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements.Q3 loss per share $0.63.Q3 revenue $4.1 million versus $900,000.Q3 revenue view $1.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

FDA approves Tetraphase Pharma's antibiotic

Tetraphase Pharmaceuticals Inc said on Monday U.S. health regulators approved its drug to treat complicated intra-abdominal infections, providing a new option to combat the growing threat from treatment-resistant bacteria.